Prosecution Insights
Last updated: November 20, 2026
Application No. 19/128,394

PREPOLYMERS AND COMBINATIONS THEREWITH FOR WOUND REGENERATION

Non-Final OA §102§103§112
Filed
May 08, 2025
Priority
Nov 08, 2022 — provisional 63/423,695 +1 more
Examiner
SCHLIENTZ, NATHAN W
Art Unit
1616
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sunnybrook Health Sciences Centre
OA Round
1 (Non-Final)
41%
Grant Probability
Moderate
1-2
OA Rounds
2y 1m
Est. Remaining
23%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
336 granted / 815 resolved
-18.8% vs TC avg
Minimal -19% lift
Without
With
+-18.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
43 currently pending
Career history
881
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
41.5%
+1.5% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 815 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 6, 18-21, 24-26, 29-30, 33, 36-37, 45-48 and 51-53 are pending. Information Disclosure Statement The information disclosure statement (IDS) submitted on 8 May 2025 was filed before the mailing of an Office action. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 21 and 36 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 21, the term “variant” renders the claim indefinite because it is unclear what compounds or peptides are within the scope of a variant of the claimed sequence. The instant specification states that variants are biologically active constructs, proteins, antibodies, or fragments thereof having an amino acid sequence that differs from a comparator sequence by virtue of an insertion, deletion, modification and/or substitution of one or more amino acid residues within the comparative sequence. The definition does not provide any limitations to the type or size of modification of the comparative sequence. Therefore, it is unclear what peptides or compounds are within the scope of the instant claims. Also, regarding claims 21 and 51, the recitation “the peptide comprises or consists of the sequence…” is interpreted to mean that the peptide can be the exact length and sequence as written or a longer peptide containing the claimed sequence. The term “fragment” thereof is interpreted to include a smaller portion of the peptide sequence (e.g., 2-11 amino acid sequence), a single amino acid (i.e., G, P, Q, G, I, W, or K) and functional groups such as CH2, C(O), NH, etc. Regarding claim 36, the phrases “such as” and “including” renders the claim indefinite because it is unclear whether the limitations following the phrases are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Parekkadan et al. (WO 2019/104154 A1). Regarding claim 1, Parekkadan et al. disclose pegylated products comprising the reaction product of acrylate-PEG-SVA and a peptide (Tables 3-4). Parekkadan et al. disclose the reaction product of acrylate-PEG-SVA and a degradable peptide of sequence GGGPQG↓IWGQGK, wherein ↓ indicates a cleavage point by collagenase between the leucine and glycine residues ([00136]; Table 5). Parekkadan et al. disclose the structure acryl-PEG-peptide-PEG-acryl ([00136]). Claims 1, 6, 18-21, 24-26, 33, 36, 46 and 51-53 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Martinez et al. (Biorxiv, 2021). Regarding claims 1 and 21, Martinez et al. disclose Ac-PEG-PQ-PEG-Ac, wherein Ac is acrylate, and PQ is the MMP-labile peptide KGGGPQG↓IWGQGK (↓ denotes cleavage site) (Section 2.3). Regarding claims 6, 18, 24-25 and 51-52, Martinez et al. disclose combining thiolated hyaluronic acid with the PEG prepolymer (Section 2.5; Fig. 1). Regarding claims 19-20 and 53, Martinez et al. disclose that the peptide was reacted with Acrylate-PEG-succinimidyl valerate (Ac-PEG-SVA) (Section 2.3). Regarding claim 26, Martinez et al. disclose that for cell encapsulations, HA-SH working solution and acrylated pendant peptide solution were first mixed and allowed to react for 30 minutes. Crosslinker working solutions were added to the above HA solutions, reacted for 5 minutes, and the total hydrogel solution was used to gently resuspend the prepared cell pellets until the hydrogel suspension was uniform (Section 2.5). Regarding claims 33, 36 and 46, Martinez et al. disclose hydrogel-cell suspensions (Section 2.5). Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lanfer et al. (EP 3 181 152 A1). Regarding claim 1, Lanfer et al. disclose the preparation of the star-PEG hydrogel comprising: a. Synthesis of RGD-PEG: RGDS peptide (obtained via solid state synthesis) is dissolved in anhydrous dimethyl sulfoxide with 2 µl diisopropylethylamine and then added dropwise to dry acryolyl-4 arm PEG-succinimidyl carboxymethyl at a molar ration of 1:1.2; b. The product is dialyzed against water with a 5000 Da molecular cut off membrane and lyophilized; c. Synthesis of the protease-sensitive peptide sequence bound to PEG: GGGPQGIWGQGK peptide (obtained via solid state synthesis) is dissolved in anhydrous dimethyl sulfoxide with 2 µl diisopropylethylamine and then added dropwise to dry acryolyl-4 arm PEG-succinimidyl carboxymethyl at a molar ration of 2:1; d. The product is dialyzed against water with a 5000 Da molecular cut off membrane and lyophilized; e. Formation of hydrogels: mixing of product from 6.c. (10 % w/v) in sterile HEPES-buffered saline with 1.5 % triethanolamine and 3.95 µl N-vinyl-2-pyrrolidone (NVP); f. Addition of 5 mM RGD-PEG (product from 6.a.) to the solution in 6.e. and addition of this mixture onto a layer of BNC; g. Hydrogel and BNC layer are connected by standard technologies known to the art, such as 'biological glue' (e.g. fibrin glue) as mentioned above, or by means of standard chemical binding reactions; and h. Cross-linking of hydrogels with white light for 35 seconds ([0199]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 6, 18-21, 25-26, 29-30, 33, 36, 46 and 51-52 are rejected under 35 U.S.C. 103 as being unpatentable over Parekkadan et al. (WO 2019/104154 A1) as applied to claim 1 above. The teachings of Parekkadan et al. are discussed above and incorporated herein. Regarding claim 6, Parekkadan et al. do not explicitly disclose a combination comprising [acryl-PEG-peptide-PEG-acryl]n and a thiolated biomolecule, as instantly claimed. However, Parekkadan et al. teach degradable hydrogels, wherein non-enzymatic methods of polymer degradation can also be included in methods and systems of the present invention, such as thiol functionalized PEG macromers can be used to provide degradability in response to reducing microenvironments, such as in the presence of glutathione ([00138]). Therefore, it would have been prima facie obvious for a person of ordinary skill in the art prior to the effective filing date of the instant claims to prepare the hydrogel compositions according to Parekkadan et al. comprising [acryl-PEG-peptide-PEG-acryl]n and a thiol functionalized PEG in order to prepare degradable hydrogels. Regarding claims 18 and 51, Parekkadan et al. teach that the PEG will be terminated with a thiol group to form PEG-diester-dithiol cross-linker ([00138]). Regarding claims 19-20, Parekkadan et al. teach the acrylate-PEG-SVA ([00136]; Tables 3-5). Regarding claim 21, Parekkadan et al. teach the degradable peptide of sequence GGGPQG↓IWGQGK, wherein ↓ indicates a cleavage point by collagenase between the leucine and glycine residues ([00136]; Table 5). Regarding claim 25, Parekkadan et al. teach combining the peptide and the acrylate-PEG-SVA ([00136]; Tables 3-5). Regarding claim 26, Parekkadan et al. teach the reaction product of the same peptide and acrylate-PEG-SVA as the instant invention. Therefore, in the absence of evidence to the contrary, the polymerization will occur in the same amount of time as instantly claimed. Regarding claims 29-30, Parekkadan et al. teach that the polymerization can occur with a photoinitiator, such as triethanolamine, 1-vinyl-2-pyrrolidinone (NVP) and eosin Y disodium salt ([00127]; Fig. 29). Regarding claim 33, Parekkadan et al. teach that the hydrogel is biodegradable and supports cell viability ([00134]-[00138]; Claim 1). Regarding claim 36, Parekkadan et al. teach the capsule further comprising a cell adhered to a substrate, wherein the adherent cell is a selected from the group consisting of a stem cell, a pancreatic islet, a peripheral blood mononuclear cell, an endothelial progenitor cell, a blood fibrocyte, a bone marrow cell, a T cell, a B cell, a dendritic cell, an NK cell, a monocyte, a CD34+ cell, a hepatocyte, a gastrointestinal cell, a skin cell, a skin progenitor cell, a cancer cell, a hybridoma cell, a prokaryotic cell, a HEK293T packaging cell, a yeast cell, a pancreatic precursor cell, a Mesenchymal Stem Cell (MSCs), a Chinese Hamster Ovary (CHO) cell, a Madin-Darby Canine Kidney Epithelial (MDCK) cell, and a Vero cell, a neural stem cell, an embryonic stem cell, and a pluripotent stem cell (Claims 27-29). Regarding claim 46, Parekkadan et al. teach a hydrogel (Claim 3). Regarding claim 52, Parekkadan et al. teach the PEG will be terminated with a thiol group to form PEG-diester-dithiol cross-linker, and the hydrogel is cross-linked ([0013]-[0014], [00138]; Claims 4 and 39-42). Claims 6, 18-21, 24-26, 29-30, 33, 36-37, 45-48 and 51-53 are rejected under 35 U.S.C. 103 as being unpatentable over Lanfer et al. (EP 3 181 152 A1) as applied to claim 1 above. Regarding claims 6, 18, 24-25 and 51-53, Lanfer et al. do not explicitly disclose the acryl-PEG-peptide-PEG-acryl prepolymer combined with a thiolated biomolecule, as instantly claimed. However, Lanfer et al. teach that in certain embodiments of the invention, the hydrogel comprises a hyaluronan (or a functionalized/derivatized hyaluronan) and a gelatin (or a functionalized/derivatized gelatin) ([0109]); wherein the hyaluronan and the gelatin are each thiolated. In certain embodiments the hyaluronan and the gelatin have each been thiol-modified using carbodiimide mediated hydrazide chemistry. In certain embodiments a hyaluronan sodium salt is used. In certain embodiments an acrylated hyaluronic acid is used. In certain embodiments the hyaluronan derivative and gelatin derivative are crosslinked. In some embodiments, the gel-forming material is based on chemically-modified hyaluronic acid ([0110]). Another example of a crosslinked hydrogel comprises thiol-modified hyaluronan and thiol-modified heparin (which can ionically bind a wide variety of growth factors and slowly releases them over time) reacted with a thiol-reactive crosslinker such as polyethylene glycol diacrylate. Thiol-modified heparin allows the slow release of growth factors (GFs) within an easily customizable environment ([0111]). In certain embodiments, the hydrogel is just formulated with a thiolated hyaluronan and a thiolated heparin. This hydrogel is a synthetic extracellular matrix (ECM) that can be crosslinked in situ. Unlike an animal-derived extracellular matrix (ECM), the hydrogel is chemically defined and is typically non immunogenic. In certain embodiments the hydrogel is formulated with a thiolated hyaluronan, a thiolated heparin, and a thiolated gelatin. In various embodiments the immobilized heparin in the hydrogel mimics the heparin sulfate proteoglycans normally present in the extracellular matrix (ECM). It also helps protect growth factors from proteolysis and slows their release to attached cells. This reduces the amount of growth factor required to achieve stimulation of cell growth or differentiation when compared to the use of free growth factor in media ([0112]). Another example of a crosslinked hydrogel comprises thiol-modified hyaluronan and thiol-modified heparin reacted with a thiol-reactive crosslinker such as polyethylene glycol diacrylate ([0113]). See also [0198]. Therefore, it would have been prima facie obvious for a person of ordinary skill in the art prior to the effective filing date of the instant claims to combine a thiolated hyaluronan, a thiolated heparin, and/or a thiolated gelatin with the PEG prepolymer of Lanfer et al. A person of ordinary skill in the art would have been motivated to include the thiolated hyaluronan, heparin or gelatin in order to allow the slow release of growth factors (GFs) within an easily customizable environment, protect growth factors from proteolysis and slows their release to attached cells, and achieve stimulation of cell growth or differentiation. Regarding claim 19, Lanfer et al. teach acryolyl-4 arm PEG-succinimidyl carboxymethyl ([0199]). Regarding claim 21, Lanfer et al. teach the GGGPQGIWGQGK peptide ([0199]). Regarding claims 26 and 29-30, Lanfer et al. teach the composition comprising triethanolamine and N-vinyl-2-pyrrolidone (NVP), and cross-linking of hydrogels with white light for 35 seconds ([0199]). Regarding claims 33 and 36, Lanfer et al. teach mixing a cell suspension with a precursor solution (i.e., a solution comprising a polymer suitable for hydrogel formation) and crosslinking the resulting network ([0211]). Regarding claims 37, 45 and 47-48, Lanfer et al. teach a wound care product for plastic surgery, tissue engineering and for treatment of acute and chronic wounds ([0001], [0017]). Regarding claim 46, Lanfer et al. teach a hydrogel ([0199]). Conclusion No claim is allowed at this time. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nathan W Schlientz whose telephone number is (571)272-9924. The examiner can normally be reached 10:00 AM to 6:00 PM, Monday through Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at (571) 272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.W.S/Examiner, Art Unit 1616 /ERIN E HIRT/Primary Examiner, Art Unit 1616
Read full office action

Prosecution Timeline

May 08, 2025
Application Filed
Nov 03, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12796683
DISINFECTANT SYSTEM
3y 12m to grant Granted Nov 17, 2026
Patent 12727598
SURFACTANT COMPOSITION AND USE THEREOF
5y 6m to grant Granted Sep 08, 2026
Patent 12721290
LEAF VEIN ABSORPTION METHOD AND FUNCTIONAL MODIFICATION MATERIAL FOR PLANT
2y 8m to grant Granted Sep 01, 2026
Patent 12714102
USE OF DIAMINOMETHANAL CARBOXYLIC ACID COMPLEXES AS AGRICULTURAL SPRAY ADJUVANTS
4y 5m to grant Granted Aug 25, 2026
Patent 12714097
COMPOSITIONS AND SYSTEMS FOR DISINFECTION
3y 11m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
41%
Grant Probability
23%
With Interview (-18.6%)
3y 7m (~2y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 815 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month